Jeet Mukherjee

“First, just any thoughts on the delay behind Pacific 9 and what implications that may have on active and control arm performance? And the second being, you know, following the triple meeting for 4502, what can we expect as next steps for the program?”

“First, just any thoughts on the delay behind Pacific 9 and what implications that may have on active and control arm performance? And the second being, you know, following the triple meeting for 4502, what can we expect as next steps for the program?”

“Maybe just to dig a little bit further into some of these upcoming readouts, just how should we think about setting expectations for Polaris 1, 2, and Glora 4?”

“Just for the broadened data that's coming up by year end, could you comment if there's a cap on the number of patients who are on prior biologics and will you ultimately break out the data by patients who are on prior biologics versus those who are not?”

“You know, so you spoke to the high level of patient interest for your DSAP study, but can you speak to patient enthusiasm for the LO-2 trial? And subsequently, what change on the AK, IGA, or PGIC scales would you deem differentiated or meaningful here in this view as we look ahead to that data in 2027?”